CR20210026A - Modificaciones de cristales de odevixibat - Google Patents
Modificaciones de cristales de odevixibatInfo
- Publication number
- CR20210026A CR20210026A CR20210026A CR20210026A CR20210026A CR 20210026 A CR20210026 A CR 20210026A CR 20210026 A CR20210026 A CR 20210026A CR 20210026 A CR20210026 A CR 20210026A CR 20210026 A CR20210026 A CR 20210026A
- Authority
- CR
- Costa Rica
- Prior art keywords
- odevixibat
- crystal
- crystal modifications
- crystal modification
- modifications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Liquid Crystal Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>La presente invención se refiere a modificaciones de cristales de 1,1-dioxo-3,3-dibutil-5-fenil-7-metiltio-8-(N-{(R) -α-[N-((S)-1- carboxipropil)carbamoil]-4-hidroxibencil}carbamoilmetoxi) 2,3,4,5-tetrahidro-1,2,5-benzotiadiazepina(odevixibat), más específicamente modificaciones de cristales 1 y 2 de odevixibat. La invención también se refiere a un proceso para la preparación<strong> </strong>de la modificación de cristal 1 de odevixibat, a una composición farmacéutica que comprende la modificación de cristal 1 y al uso de esta modificación cristalina en el tratamiento de diversas afecciones como se describe en este documento.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1850761 | 2018-06-20 | ||
SE1850762 | 2018-06-20 | ||
PCT/SE2019/050602 WO2019245448A1 (en) | 2018-06-20 | 2019-06-20 | Crystal modifications of odevixibat |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210026A true CR20210026A (es) | 2021-03-18 |
Family
ID=67138007
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210026A CR20210026A (es) | 2018-06-20 | 2019-06-20 | Modificaciones de cristales de odevixibat |
CR20210027A CR20210027A (es) | 2018-06-20 | 2019-06-20 | Formulación farmacéutica de odevixibat |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210027A CR20210027A (es) | 2018-06-20 | 2019-06-20 | Formulación farmacéutica de odevixibat |
Country Status (21)
Country | Link |
---|---|
US (4) | US11802115B2 (es) |
EP (2) | EP3810581A1 (es) |
JP (2) | JP7448490B2 (es) |
KR (2) | KR20210024033A (es) |
CN (1) | CN112312893A (es) |
AU (2) | AU2019290338B2 (es) |
BR (2) | BR112020024479A2 (es) |
CA (2) | CA3100691A1 (es) |
CL (2) | CL2020003295A1 (es) |
CO (2) | CO2020015781A2 (es) |
CR (2) | CR20210026A (es) |
EC (2) | ECSP21000999A (es) |
IL (2) | IL279464A (es) |
JO (2) | JOP20200299A1 (es) |
MX (2) | MX2020013839A (es) |
NI (2) | NI202000104A (es) |
PE (2) | PE20210182A1 (es) |
PH (2) | PH12020552165A1 (es) |
SG (2) | SG11202012170PA (es) |
TW (1) | TWI823954B (es) |
WO (2) | WO2019245448A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2637668B1 (en) | 2010-11-08 | 2016-05-11 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Eaファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20210024033A (ko) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | 오데빅시바트의 약학 제제 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
CN113913436B (zh) * | 2021-11-18 | 2023-09-29 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 逆转录转座基因l1-atp8b1及其作为肺鳞癌标志物的用途和治疗肺鳞癌的药物 |
WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
WO2024094841A1 (en) | 2022-11-03 | 2024-05-10 | Albireo Ab | Treating alagille syndrome (algs) |
WO2024121431A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Cocrystals of odevixibat |
Family Cites Families (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
GB1573487A (en) | 1977-05-23 | 1980-08-28 | Bristol Myers Co | Bile acid binding composition |
DE3066728D1 (en) | 1979-04-30 | 1984-03-29 | Max Planck Gesellschaft | Tyrosine derivatives, process for their production and their use in the synthesis of peptides |
CA1313135C (en) | 1987-02-09 | 1993-01-26 | The Dow Chemical Company | Cholestyramine composition and process for its preparation |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
JP2800242B2 (ja) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | 粒剤の製造方法 |
DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
IL95574A (en) | 1989-09-09 | 1994-11-11 | Knoll Ag | Colstiramine preparation |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
ATE144988T1 (de) | 1990-12-06 | 1996-11-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindung als arzneimittel |
NZ245503A (en) | 1991-12-20 | 1995-11-27 | Hoechst Ag | Polymers containing bile acids; pharmaceuticals and preparatory methods |
JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
US5578316A (en) | 1992-06-04 | 1996-11-26 | Smithkline Beecham Corporation | Palatable pharmaceutical compositions |
ATE160783T1 (de) | 1992-06-12 | 1997-12-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel |
US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
ES2149250T3 (es) | 1993-04-23 | 2000-11-01 | Novartis Ag | Dispositivo para la administracion de medicamentos con liberacion controlada. |
TW289021B (es) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
TW289757B (es) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
TW289020B (es) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
DK0781278T3 (da) | 1994-09-13 | 2001-04-17 | Monsanto Co | Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US6069167A (en) | 1996-01-16 | 2000-05-30 | University Technology Corporation | Use of antioxidant agents to treat cholestatic liver disease |
DE19608592A1 (de) | 1996-03-06 | 1997-09-11 | Hoechst Ag | Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices |
WO1997033882A1 (en) | 1996-03-11 | 1997-09-18 | G.D. Searle And Co. | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
WO1997044043A1 (en) | 1996-05-23 | 1997-11-27 | Novartis Ag | Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) |
EP0912861B1 (de) | 1996-07-24 | 2000-11-29 | Zumtobel Staff GmbH | Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter |
DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
EP0971744A2 (en) | 1997-03-11 | 2000-01-19 | G.D. SEARLE & CO. | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
ES2198613T3 (es) | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
AU7552198A (en) | 1997-06-11 | 1998-12-30 | Sankyo Company Limited | Benzylamine derivatives |
AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
US5900233A (en) | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
WO1999032478A1 (en) | 1997-12-19 | 1999-07-01 | G.D. Searle & Co. | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
BR9910035A (pt) | 1998-04-24 | 2000-12-26 | Fujisawa Pharmaceutical Co | Derivados de guanidina |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6355672B1 (en) | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
IL143944A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
HUP0104793A2 (en) | 1998-12-23 | 2002-06-29 | Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
IL143938A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
MXPA01006470A (es) | 1998-12-23 | 2003-06-06 | Searle Llc | Combinaciones de inhibidores de transporte de acido biliar ileal y agentes de secuentro de acido biliar para indicaciones cardiovasculares. |
ES2200587T3 (es) | 1998-12-23 | 2004-03-01 | G.D. Searle Llc | Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares. |
JP2002536440A (ja) | 1999-02-12 | 2002-10-29 | ジー.ディー.サール エルエルシー | 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規1,2−ベンゾチアゼピン |
DE19915420A1 (de) | 1999-04-06 | 2000-10-12 | Basf Ag | Stabilisierte Polyvinylpyrrolidon-Zubereitungen |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
US20020054903A1 (en) | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
WO2001034570A1 (fr) | 1999-11-08 | 2001-05-17 | Sankyo Company, Limited | Derives heterocycliques azotes |
GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
CA2400021A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
EP1286984A2 (en) | 2000-03-10 | 2003-03-05 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
DE60106623T2 (de) | 2000-07-28 | 2006-02-02 | F. Hoffmann-La Roche Ag | Neue pharmazeutische zusammensetzung |
FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
US20040038862A1 (en) | 2001-07-30 | 2004-02-26 | Goodwin Bryan James | Identification of new therapeutic targets for modulating bile acid synthesis |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
JP3616635B2 (ja) | 2001-09-08 | 2005-02-02 | アストラゼネカ アクチボラグ | 高脂質血症の治療のための回腸胆汁酸運搬(ibat)阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体 |
CA2460330A1 (en) | 2001-09-12 | 2003-03-20 | G.D. Searle Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
WO2003040127A1 (en) | 2001-11-02 | 2003-05-15 | G.D. Searle Llc | Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
US20040014806A1 (en) | 2002-03-08 | 2004-01-22 | Pharmacia Corporation | Methods and compositions for lowering levels of blood lipids |
EP1490029A4 (en) | 2002-03-22 | 2006-02-22 | Ranbaxy Lab Ltd | DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
EP1535913B1 (en) | 2002-08-28 | 2011-11-02 | Asahi Kasei Pharma Corporation | Novel quaternary ammonium compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
WO2004076657A2 (en) | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
US20060210633A1 (en) | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CA2584188C (en) | 2003-10-16 | 2014-03-18 | Techcom Group, Llc | Reduced digestible carbohydrate food having reduced blood glucose response |
CN102293773A (zh) | 2004-02-27 | 2011-12-28 | 旭化成制药株式会社 | 含有苯并硫氮杂卓和苯并虑平化合物的药物 |
US20050197376A1 (en) | 2004-03-02 | 2005-09-08 | Fujisawa Pharmaceutical Co. Ltd. | Concomitant drugs |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
US20050287178A1 (en) | 2004-06-23 | 2005-12-29 | Steed Barrie L | Diagnosis and treatment of heavy gallbladder densities |
JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
EP1877373A2 (en) | 2005-05-05 | 2008-01-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
US20080193543A1 (en) | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
EP1928499B1 (en) | 2005-09-20 | 2011-06-29 | Novartis AG | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
CA2649161A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Cgrp antagonist salt |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
JP2010509252A (ja) | 2006-11-14 | 2010-03-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 改善された特性を有する新規な1,4−ベンゾチエピン−1,1−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用 |
DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
WO2008091540A2 (en) | 2007-01-19 | 2008-07-31 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as tgr5 modulators and methods of use thereof |
DE602008002073D1 (de) | 2007-03-02 | 2010-09-16 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
HUE043897T2 (hu) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
RU2011112694A (ru) | 2008-09-02 | 2012-10-10 | Юсв Лимитед (In) | Сшитые полимеры |
JP2012509891A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ,インク. | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
WO2011075539A2 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
WO2011104275A1 (en) | 2010-02-23 | 2011-09-01 | Da Volterra | Formulations for oral delivery of adsorbents in the gut |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
KR20130132846A (ko) | 2010-11-08 | 2013-12-05 | 알비레오 에이비 | 대사 장애들 및 관련 질환들의 치료용 ⅰbat 억제제들 |
US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
SG190433A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
EP2637668B1 (en) | 2010-11-08 | 2016-05-11 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
EP2771003B1 (en) * | 2011-10-28 | 2017-04-19 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
EP2770990A4 (en) | 2011-10-28 | 2015-03-11 | Lumena Pharmaceuticals Inc | Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease |
WO2013168671A1 (ja) | 2012-05-07 | 2013-11-14 | キッセイ薬品工業株式会社 | ピラゾール誘導体及びその医薬用途 |
CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
US9724319B2 (en) | 2014-02-27 | 2017-08-08 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US20170143743A1 (en) | 2014-06-16 | 2017-05-25 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Eaファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
KR102296314B1 (ko) | 2014-06-25 | 2021-09-01 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 안정화 방법 |
KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
CN105985254B (zh) | 2015-02-17 | 2018-03-16 | 上海中科绿碳化工科技有限公司 | 一种制备甲酰胺类化合物的方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
AU2019232477A1 (en) | 2018-03-09 | 2020-09-10 | Elobix Ab | Process for the preparation of elobixibat |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20210024033A (ko) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | 오데빅시바트의 약학 제제 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US20200046757A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations, and uses thereof |
US20200046758A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
LT3921028T (lt) | 2019-02-06 | 2023-02-10 | Albireo Ab | Benzotiadiazepino junginiai ir jų naudojimas kaip tulžies rūgšties moduliatorių |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
BR112021015815A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para tratar colestase |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
-
2019
- 2019-06-20 KR KR1020217001712A patent/KR20210024033A/ko unknown
- 2019-06-20 PE PE2020002089A patent/PE20210182A1/es unknown
- 2019-06-20 JP JP2020570778A patent/JP7448490B2/ja active Active
- 2019-06-20 JO JOP/2020/0299A patent/JOP20200299A1/ar unknown
- 2019-06-20 JO JOP/2020/0297A patent/JOP20200297A1/ar unknown
- 2019-06-20 WO PCT/SE2019/050602 patent/WO2019245448A1/en active Application Filing
- 2019-06-20 CR CR20210026A patent/CR20210026A/es unknown
- 2019-06-20 WO PCT/SE2019/050603 patent/WO2019245449A1/en active Application Filing
- 2019-06-20 CR CR20210027A patent/CR20210027A/es unknown
- 2019-06-20 EP EP19734937.6A patent/EP3810581A1/en active Pending
- 2019-06-20 MX MX2020013839A patent/MX2020013839A/es unknown
- 2019-06-20 AU AU2019290338A patent/AU2019290338B2/en active Active
- 2019-06-20 KR KR1020217001711A patent/KR20210024032A/ko unknown
- 2019-06-20 CA CA3100691A patent/CA3100691A1/en active Pending
- 2019-06-20 AU AU2019290337A patent/AU2019290337B2/en active Active
- 2019-06-20 EP EP19735664.5A patent/EP3810084A1/en active Pending
- 2019-06-20 BR BR112020024479-1A patent/BR112020024479A2/pt unknown
- 2019-06-20 SG SG11202012170PA patent/SG11202012170PA/en unknown
- 2019-06-20 CN CN201980041077.4A patent/CN112312893A/zh active Pending
- 2019-06-20 US US16/477,160 patent/US11802115B2/en active Active
- 2019-06-20 CA CA3100687A patent/CA3100687A1/en active Pending
- 2019-06-20 PE PE2020002088A patent/PE20210136A1/es unknown
- 2019-06-20 JP JP2020570784A patent/JP7504032B2/ja active Active
- 2019-06-20 BR BR112020024461-9A patent/BR112020024461A2/pt unknown
- 2019-06-20 SG SG11202012151XA patent/SG11202012151XA/en unknown
- 2019-06-20 MX MX2020013774A patent/MX2020013774A/es unknown
- 2019-06-20 TW TW108121584A patent/TWI823954B/zh active
- 2019-07-10 US US16/508,036 patent/US10975046B2/en active Active
-
2020
- 2020-10-07 US US17/065,245 patent/US11365182B2/en active Active
- 2020-12-14 PH PH12020552165A patent/PH12020552165A1/en unknown
- 2020-12-15 PH PH12020552168A patent/PH12020552168A1/en unknown
- 2020-12-15 CO CONC2020/0015781A patent/CO2020015781A2/es unknown
- 2020-12-15 IL IL279464A patent/IL279464A/en unknown
- 2020-12-15 NI NI202000104A patent/NI202000104A/es unknown
- 2020-12-15 NI NI202000103A patent/NI202000103A/es unknown
- 2020-12-15 CO CONC2020/0015772A patent/CO2020015772A2/es unknown
- 2020-12-15 IL IL279468A patent/IL279468A/en unknown
- 2020-12-18 CL CL2020003295A patent/CL2020003295A1/es unknown
- 2020-12-18 CL CL2020003296A patent/CL2020003296A1/es unknown
-
2021
- 2021-01-07 EC ECSENADI2021999A patent/ECSP21000999A/es unknown
- 2021-01-08 EC ECSENADI20211547A patent/ECSP21001547A/es unknown
-
2022
- 2022-05-13 US US17/744,429 patent/US20220281832A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210026A (es) | Modificaciones de cristales de odevixibat | |
MD3681864T2 (ro) | Modulatori ai proteinei reglatoare a conductanței transmembranare în fibroza chistică și metode de utilizare | |
EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
EP1673078A4 (en) | BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
EA201100956A1 (ru) | Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта | |
WO2009052396A3 (en) | Novel process for solubilizing protein from a proteinaceous material and compositions thereof | |
DE602004014361D1 (de) | Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen | |
EA201170571A1 (ru) | Способы и композиции для улучшения когнитивной функции | |
MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
RU2005128792A (ru) | Применение ингибитора ibat для лечения или профилактики запора | |
DE602004020657D1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
DE60318839D1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
DE69912930D1 (de) | Neue salzformn von (2e)-5-amino-5-methylhex-2-enolsäure n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phruylrthyl) carbamoyl)-2-(2-naphtyl)ethyl)amid | |
ATE495164T1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
EA202190888A1 (ru) | Пептид для применения в косметике | |
ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
DE60110043D1 (de) | Methode zur synthetisierung von leflunomid | |
DE60108094D1 (de) | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien | |
DE60334986D1 (de) | Muteine des placental growth factor type 1, herstellungsmethode und anwendung davon | |
MA29523B1 (fr) | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis | |
MA29522B1 (fr) | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire | |
TW200635910A (en) | Dipeptide nitriles | |
ATE528299T1 (de) | Cyclische ketale als beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit |